Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial - Rha, SY; Oh, DY; Yañez, P (Lancet Oncol, 2023)